Similar articles for PMID: 31811061

Year	Number of Results
2002	1
2003	1
2006	2
2008	2
2009	4
2010	1
2011	2
2012	2
2013	4
2014	3
2015	8
2016	13
2017	14
2018	16
2019	20
2020	3
2021	2

1

Assessing PET Parameters in Oncologic ¹⁸F-FDG Studies.

Sarikaya I, Sarikaya A. Sarikaya I, et al. J Nucl Med Technol. 2020 Sep;48(3):278-282. doi: 10.2967/jnmt.119.236109. Epub 2019 Dec 6. J Nucl Med Technol. 2020. PMID: 31811061

2

Metabolic Tumor Burden Assessed by Dual Time Point [¹⁸F]FDG PET/CT in Locally Advanced Breast Cancer: Relation with Tumor Biology.

Garcia-Vicente AM, Pérez-Beteta J, Pérez-García VM, Molina D, Jiménez-Londoño GA, Soriano-Castrejón A, Martínez-González A. Garcia-Vicente AM, et al. Mol Imaging Biol. 2017 Aug;19(4):636-644. doi: 10.1007/s11307-016-1034-x. Mol Imaging Biol. 2017. PMID: 27981471

3

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

4

Does whole-body Patlak ¹⁸F-FDG PET imaging improve lesion detectability in clinical oncology?

Fahrni G, Karakatsanis NA, Di Domenicantonio G, Garibotto V, Zaidi H. Fahrni G, et al. Eur Radiol. 2019 Sep;29(9):4812-4821. doi: 10.1007/s00330-018-5966-1. Epub 2019 Jan 28. Eur Radiol. 2019. PMID: 30689031

5

Revisiting Weight-Normalized SUV and Lean-Body-Mass-Normalized SUV in PET Studies.

Sarikaya I, Albatineh AN, Sarikaya A. Sarikaya I, et al. J Nucl Med Technol. 2020 Jun;48(2):163-167. doi: 10.2967/jnmt.119.233353. Epub 2019 Oct 11. J Nucl Med Technol. 2020. PMID: 31604893

6

Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.

Ciftci E, Turgut B, Cakmakcilar A, Erturk SA. Ciftci E, et al. Nucl Med Commun. 2017 Sep;38(9):788-794. doi: 10.1097/MNM.0000000000000712. Nucl Med Commun. 2017. PMID: 28692494

7

Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.

Kim YI, Cheon GJ, Paeng JC, Cho JY, Kang KW, Chung JK, Kim EE, Lee DS. Kim YI, et al. Nucl Med Commun. 2014 Jun;35(6):606-12. doi: 10.1097/MNM.0000000000000101. Nucl Med Commun. 2014. PMID: 24598843

8

Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.

Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, Boellaard R. Kramer GM, et al. J Nucl Med. 2016 Sep;57(9):1343-9. doi: 10.2967/jnumed.115.170225. Epub 2016 Apr 21. J Nucl Med. 2016. PMID: 27103020 Free article.

9

Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.

Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, Wakabayashi H, Satoh K, Ohkawa M. Nishiyama Y, et al. J Nucl Med. 2006 Apr;47(4):633-8. J Nucl Med. 2006. PMID: 16595497 Free article.

10

Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.

Dimitrakopoulou-Strauss A, Strauss L. Dimitrakopoulou-Strauss A, et al. Hell J Nucl Med. 2006 Jan-Apr;9(1):10-21. Hell J Nucl Med. 2006. PMID: 16617388

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed